The Future of Drug Discovery Isn’t Predicted - It’s Seen

We believe the only way to discover better, life-changing drugs is by seeing diseases in action, not guessing them.

That’s why at Anima Biotech, we’ve built the AI platform that thinks, sees, and learns biology at the core of disease mechanisms, inside real patient-derived cells.

Anima Biotech is a TechBio pioneer, transforming target and drug discovery with Lightning.AI - the first Visual Biology loop where Computational and Experimental AI agents iteratively think, see, and learn disease pathways, turning the undruggable into tomorrow’s therapies.

Lightning.AI runs two AIs in one discovery loop - Computational AI that thinks of thousands of hypotheses from omics and literature, and Experimental AI that sees in those ideas unfold in cells and learns with its two neural networks, using our PathwayLight technologies.

Together, they discover targets that matter backed by direct biological evidence and identify modulation strategies for hard-to-drug targets, discovering small molecules tailored to their mRNA biology across mechanisms.

Validated by partnerships with Abbvie, Takeda and Lilly, and with 20 pipeline programs across oncology, neurology, immunology, and rare disease, Anima Biotech is proving with its unique Visual Biology approach that the future of target and drug discovery isn’t predicted - it’s seen.